Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C
Introduction: The WHO estimates that 180 million people are chronically infected with hepatitis C virus (HCV) throughout the world. Despite the emergence of new therapies, the combination of pegylated interferon and ribavirin remains the accepted standard of care in low-income countries, including M...
Saved in:
| Main Authors: | Jorge Luis Sandoval-Ramirez, José Antonio Mata-Marín, Gloria Huerta García, Jesús Enrique Gaytán-Martínez |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2015-03-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/5284 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C
by: O. O. Znoyko, et al.
Published: (2014-09-01) -
Therapy of chronic hepatitis C: Virologic response monitoring
by: Kuljić-Kapulica Nada, et al.
Published: (2010-01-01) -
DORNASE ALFA: WHAT EFFECTIVENESS OF MEDICATION DEPENDS ON?
by: O.I. Simonova
Published: (2009-07-01) -
DETERMINATION OF DARBEPOETIN ALFA IN RABBIT PLASMA BY ELISA
by: M. V. Karlina, et al.
Published: (2019-01-01) -
Telaprevir: options of application in separate patient groups
by: M. V. Mayevskaya, et al.
Published: (2013-10-01)